Herceptin provides impressive survival benefit for patients with high levels of HER2
- Details
- Category: Roche
A detailed analysis of the Phase III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin).
Results of ADAGIO study with Azilect® in Parkinson's disease published
- Details
- Category: Lundbeck
H. Lundbeck A/S' (Lundbeck) partner Teva Phamaceuticals Industries Ltd. (Teva) announced that results from the ADAGIO trial, published online in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving Azilect® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group)(1).
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo controlled Phase II trial showing that Nexavar® (sorafenib tablets) in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer by 74 percent.
Analysis of BRAIN study shows that patients may have a stabilisation or improvement
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that an analysis of the phase II BRAIN study of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM) demonstrated that in addition to increasing the chance of patients being alive without worsening of their disease at six months (progression free survival; PFS-6*(1), Avastin-based therapy may also lead to additional positive impact on patients' daily lives(2).
Denosumab Demonstrates Superiority Over Zometa(R)
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer's pending acquisition of Wyeth.
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
- Details
- Category: Bayer
Bayer Schering Pharma announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar® (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin™ - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in
Berlin, Germany.
More Pharma News ...
- Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress
- U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine
- Novartis investigational bronchodilator QAB149 compared to tiotropium
- Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
- Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
- Two new studies report increased survival rates in Tamiflu-treated patients
- Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent